Shares of both Ultragenyx and Mereo BioPharma were seeing record selloffs after disappointing trial results for setrusumab.

Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts ...

O4, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

Furthermore, it benefits from a strong competitive edge, thanks to its relationships with third-party payers, patients, and ...

The list is topped by ABIVAX Société Anonyme ( ABVX ), with a remarkable YTD performance of +1,470.22%. Cidara Therapeutics ( ...

The bank's list of highest-conviction stock picks for 2026 spans numerous sectors and features names including Pepsi and GM.

Sanofi has agreed to acquire vaccine maker Dynavax Technologies in an all-cash deal worth $2.2 billion in total equity value.

Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro ...

In this article, we will look at the top 12 Affordable Biotech Stocks to Invest In Now. On September 4, Mizuho healthcare strategist Jared Holz appeared on CNBC’s ‘Power Lunch’ to talk about the ...

This stock is a great choice for cautious and aggressive investors.

An investor whose portfolio contains some value- or income-focused investments and some growth-oriented investments, who ...